JB Chemicals & Pharmaceuticals Ltd. (JBCHEPHARM) AI Stock Analysis

• Market Cap: ₹333.18B
• Dividend Yield: 0.86%
• Average Volume (3M): 2.67K
• Price to Earnings (P/E): 36.0
• Beta (1Y): 0.62
• Revenue Growth: 10.25%
• EPS Growth: 17.01%
• Country: IN
• Employees: 5,311
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 12.70
• Shares Outstanding: 160,558,700
• 10 Day Avg. Volume: 4,569
• 30 Day Avg. Volume: 2,671
• PEG Ratio: 1.96
• Price to Book (P/B): 7.17
• Price to Sales (P/S): 6.28
• P/FCF Ratio: 30.57
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 52.01
• Revenue Forecast (FY): ₹42.95B

• Rating: 66 Neutral
• Price Target: ₹2,216.00 ▲(19.93% Upside)
• Action: Downgraded Date: 11/01/25
• Date: Action: Downgraded 11/01/25

JB Chemicals & Pharmaceuticals Ltd. has a strong financial foundation with impressive revenue growth and profitability. However, the stock's valuation appears high, and technical indicators suggest a neutral market sentiment. The absence of earnings call insights and corporate events limits additional context.

Positive Factors

Revenue Growth & Margin Improvement

Sustained revenue growth from INR 24.2bn to INR 39.2bn alongside improving gross and net margins indicates durable demand and operational leverage. This supports predictable cash generation and reinvestment capacity, strengthening fundamentals over the next several months.

Low Leverage / Strong Balance Sheet

A low debt-to-equity profile and strong equity ratio provide financial flexibility and lower refinancing risk. This balance sheet strength allows management to fund organic growth, absorb shocks, and pursue strategic initiatives without compromising liquidity over the medium term.

Strong Cash Generation

Efficient conversion of earnings to operating cash flow and notable free cash flow growth indicate robust cash generation. Reliable free cash supports capex, working capital needs, and shareholder returns, enhancing the firm's ability to sustain operations and invest for growth.

Negative Factors

Capex Variability Risk

The noted variability in capital spending introduces uncertainty around future free cash flow. Episodic or elevated capex can strain near-term cash available for dividends, debt reduction, or R&D, making cash-flow sustainability more contingent on execution and timing of investments.

Limited Investor Disclosure / Guidance

Absence of earnings‑call highlights and explicit guidance reduces visibility into management's near-term priorities, pipeline progress, and execution risk. Limited disclosure makes it harder for investors to assess strategic clarity and near-term operational traction over the next several months.

Exposure to Competitive Branded Generics

A business focused on branded generics faces structural competition, pricing pressure, and product lifecycle challenges. Without clear differentiation or faster new-product flows, competitive dynamics in core markets could constrain margin expansion and revenue durability over time.

JB Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients in India and internationally. Its principal products include Cilnidipine, Ranitidine, and Metronidazole. The company also provides contract manufacturing services for tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners. Further, the company provides its services in gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is based in Mumbai, India.

How the Company Makes Money

JBCHEPHARM generates revenue through multiple streams, primarily from the sale of its pharmaceutical formulations and active pharmaceutical ingredients. The company markets its products through a well-established distribution network, which includes both wholesalers and retail pharmacies. Additionally, JBCHEPHARM earns revenue from exports, significantly contributing to its earnings as it caters to various international markets. The company's strategic partnerships with healthcare providers and distributors further enhance its market presence and revenue potential. Moreover, JBCHEPHARM invests in research and development to innovate and expand its product portfolio, thereby driving growth and increasing its competitive advantage in the pharmaceutical industry.

JB Chemicals & Pharmaceuticals Ltd. Financial Statement Overview

Summary

JB Chemicals & Pharmaceuticals Ltd. demonstrates strong financial performance with robust revenue growth, efficient cost management, and solid profitability metrics. The balance sheet reflects low leverage and high equity, ensuring financial stability. Cash flows are strong, though capital expenditure management requires attention for sustained growth.

Income Statement

JB Chemicals & Pharmaceuticals Ltd. has demonstrated strong revenue growth with a notable increase in total revenue from INR 24.2 billion to INR 39.2 billion in the latest annual period. The gross profit margin is impressive, reflecting efficient cost management, and the net profit margin has improved, indicating enhanced profitability. The EBIT and EBITDA margins also show a positive trajectory, supporting the company's stable financial performance.

Balance Sheet

The company's balance sheet is solid with a low debt-to-equity ratio, showcasing financial stability and low leverage risk. The return on equity is commendable, reflecting effective utilization of shareholder funds. The equity ratio is strong, indicating a healthy proportion of assets financed by equity. Overall, the balance sheet reflects financial robustness with moderate risk.

Cash Flow

JB Chemicals & Pharmaceuticals Ltd. exhibits a strong operating cash flow relative to net income, highlighting efficient cash generation from operations. The free cash flow has grown significantly, which bodes well for future investments and shareholder returns. However, fluctuations in capital expenditures could pose potential risks to sustaining cash flow growth.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	40.08B	39.18B	34.84B	31.17B	24.24B	20.06B
Gross Profit	22.34B	26.01B	13.46B	11.14B	15.61B	12.88B
EBITDA	10.81B	10.32B	9.33B	7.04B	5.82B	6.72B
Net Income	6.85B	6.60B	5.53B	4.10B	3.85B	4.48B
Balance Sheet
Total Assets	0.00	42.74B	39.94B	35.54B	26.07B	22.38B
Cash, Cash Equivalents and Short-Term Investments	4.50B	4.50B	4.60B	2.69B	566.50M	6.94B
Total Debt	0.00	278.90M	3.78B	5.72B	545.59M	449.88M
Total Liabilities	-34.33B	8.40B	10.71B	10.74B	4.69B	4.25B
Stockholders Equity	34.33B	34.33B	29.23B	24.80B	21.34B	18.10B
Cash Flow
Free Cash Flow	0.00	8.05B	5.39B	-1.39B	-5.37B	2.67B
Operating Cash Flow	0.00	9.02B	8.01B	6.26B	1.70B	3.15B
Investing Cash Flow	0.00	-2.96B	-4.08B	-9.62B	23.20M	-2.31B
Financing Cash Flow	0.00	-5.80B	-3.41B	3.57B	-1.38B	-874.23M

JB Chemicals & Pharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1847.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JBCHEPHARM, the sentiment is Positive. The current price of 1847.8 is below the 20-day moving average (MA) of 1972.34, below the 50-day MA of 1896.92, and above the 200-day MA of 1750.81, indicating a bullish trend. The MACD of 55.47 indicates Negative momentum. The RSI at 64.94 is Neutral, neither overbought nor oversold. The STOCH value of 65.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JBCHEPHARM.

JB Chemicals & Pharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AJANTPHARM	72 Outperform	₹370.40B	31.59	―	1.04%	10.74%	11.91%
PFIZER	69 Neutral	₹225.18B	40.22	―	0.69%	6.13%	35.83%
JBCHEPHARM	66 Neutral	₹333.18B	36.01	―	0.86%	10.25%	17.01%
GLAND	63 Neutral	₹295.75B	27.13	―	1.07%	-1.51%	14.27%
GLENMARK	53 Neutral	₹599.25B	35.61	―	0.24%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

JB Chemicals & Pharmaceuticals Ltd. Corporate Events

JB Chemicals & Pharmaceuticals Publishes Postal Ballot Notices for Shareholders

JB Chemicals & Pharmaceuticals has notified the stock exchange that it has published newspaper advertisements related to a postal ballot process for its shareholders. The notices, carried in the English and Gujarati editions of the Financial Express on February 23, 2026, are intended to draw members’ attention to the ongoing ballot and reflect the company’s adherence to India’s disclosure and corporate governance requirements.

The communication follows the company’s earlier dispatch of the postal ballot notice to members on February 20, 2026, and confirms that the prescribed regulatory steps for informing investors are being followed. While the specific resolutions under vote are not detailed, the move underscores the company’s reliance on postal ballots to secure shareholder approval on corporate matters and signals continued engagement with its investor base in a transparent manner.

JB Chemicals seeks shareholder nod for board overhaul via e-voting

JB Chemicals & Pharmaceuticals has launched a postal ballot process seeking shareholder approval for several board appointments, including elevating Aman Mehta to director and managing director. The exercise also covers the induction of Amal Kelshikar, Hasmukh Patel and Sudhir Menon as non-executive, non-independent directors, with voting conducted exclusively via remote e-voting between February 22 and March 23, 2026.

The move signals a significant refresh of the company’s top leadership and board composition, which could influence its strategic direction and corporate governance framework. By relying solely on electronic voting and adhering to updated SEBI and MCA guidelines, the company underscores its compliance focus and aims to ensure broader, more efficient participation from its dispersed shareholder base.

JB Chemicals & Pharmaceuticals Announces Resignations of Two Senior Presidents

JB Chemicals & Pharmaceuticals Ltd. has announced that two key senior management executives, President – Operations Kunal Khanna and President (India Business) Dilip Singh Rathore, have tendered their resignations effective from the close of business on March 5, 2026. The simultaneous departure of both the operations and India business heads represents a significant change in the company’s leadership structure and may signal an impending realignment of its operational and domestic market strategies, with potential implications for execution, continuity, and stakeholder confidence as the company navigates this transition.

JB Chemicals & Pharmaceuticals Announces Resignation of Two Senior Presidents

JB Chemicals & Pharmaceuticals Ltd. has announced the resignations of two senior executives, Mr. Kunal Khanna, President – Operations, and Mr. Dilip Singh Rathore, President (India Business), effective from the close of business on March 5, 2026. The departure of these key leaders signals a significant change in the company’s senior management structure, which may influence operational direction and strategy execution in both manufacturing operations and the India-focused business segment, and will be closely watched by stakeholders for its impact on continuity and future performance.

JB Chemicals & Pharmaceuticals Shifts Registered Office from Maharashtra to Gujarat

JB Chemicals & Pharmaceuticals Ltd. has shifted its registered office from the state of Maharashtra to the state of Gujarat, with the new location now at 302, Iscon Mall, Star India Bazar Building, Opp. Jodhpur BRTS Satellite, Ahmedabad-380015. The change has been formally approved and certified by the Ministry of Corporate Affairs and the Registrar of Companies, Ahmedabad, and the company’s Memorandum of Association has been updated so that its registered office is now officially situated in Gujarat, signaling an administrative realignment that may have implications for its corporate governance and regulatory jurisdiction, but does not alter its core business operations.

JB Chemicals Clarifies Date on Promoter Reclassification Request Filing

JB Chemicals & Pharmaceuticals Ltd. has issued a corrigendum clarifying that a request from shareholder Tau Investment Holdings Pte. Ltd. for reclassification from ‘Promoter’ to ‘Public’ under Indian listing regulations was dated 21 January 2026, not 21 October 2026 as previously stated. The company has also confirmed that the correctly dated request letter has been filed with the stock exchanges, a procedural clarification aimed at ensuring accurate regulatory disclosure and maintaining compliance transparency for investors and regulators.